Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ: BCRX )

7.710 +0.170 (+2.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,696,650
Open 7.650
Bid (Size) 7.730 (3)
Ask (Size) 7.880 (1)
Prev. Close 7.540
Today's Range 7.590 - 7.950
52wk Range 4.030 - 9.500
Shares Outstanding 185,583,896
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today
Via The Motley Fool
BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript
BCRX earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial

Performance

YTD
-1.53%
-1.53%
1 Month
-10.66%
-10.66%
3 Month
-1.91%
-1.91%
6 Month
-0.26%
-0.26%
1 Year
+50.00%
+50.00%

More News

Read More
BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
A Preview Of BioCryst Pharma's Earnings
Via Benzinga
Earnings Scheduled For February 24, 2025
Via Benzinga
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
Via FinancialNewsMedia
Exposures COVID-19
BioCryst Pharmaceuticals (BCRX) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
7 Small-Cap Stocks to Buy for Large-Scale Gains
Via InvestorPlace
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
From FN Media Group LLC
Via GlobeNewswire
3 Insider-Buy Stocks to Add to Your Watchlist Now
Via MarketBeat
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday
Via The Motley Fool
BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Perficient Shares Are Trading Higher By Around 53%? Here Are 20 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
BCRX Stock Earnings: BioCryst Pharma Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects
Via InvestorPlace
BioCryst Pharmaceuticals (BCRX) Q4 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
What's Going On With BioCryst Stock After Earnings?
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For February 26, 2024
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.